Vijaya Diagnostic Centre Ltd Q2 FY26 Earnings Analysis
Published 5 Jul 2026 | Healthcare Services | Market Cap: ₹14.3K Cr
Price
₹1,465
Market Cap
₹14.3K Cr
P/E Ratio
82.7
How does Vijaya Diagnostic Centre Ltd rank in Healthcare Services?
Compare Vijaya Diagnostic Centre Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹219 Cr, net profit ₹48 Cr.
Full financials →Earnings Summary
Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this. - EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even. - CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion. - Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even. - Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate. - The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs.
📊 Revenue & Sales Performance
- →Vijaya Diagnostic Centre targets around 15% overall year-level growth.
- →Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%.
- →Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term.
- →Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology.
- →Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier.
- →Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up.
- →Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth.
- →Strategic location choice and differentiation expected to bolster growth against competition.
- →The company is confident of surpassing prior guidance on revenue and EBITDA margin in coming periods.
📈 Profitability & Margins
- →Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.
- →EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even.
- →CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion.
- →Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even.
- →Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate.
- →The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs. guided 38%-39%.
- →Early signs indicate strong radiology growth (~16%) and improved operations post-expansion support promising operating earnings growth.
🏗️ Capital Expenditure Plans
- →FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
- →FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26.
- →CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets.
- →Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26.
- →Plans to increase hubs from current two to five by end of FY27.
- →Long-term expansion plan includes lease properties for new hubs/spokes.
- →Break-even for new centres generally expected within one year.
- →Strategic investment in technology planned with the recruitment of a new CTO to enhance IT and operational capabilities.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned fundraising through debt or equity in the transcript.
- →The company reported having a surplus cash balance of around Rs. 235 crores as of September 30, 2025, indicating a strong liquidity position.
- →Discussions around capital expenditure indicate internal funding plans (Rs.160 crores CAPEX for FY26 and Rs.100-120 crores for FY27), without reference to external fundraising.
- →No questions or management comments suggest any intention to raise funds via equity or debt in the near future.
- →Overall, Vijaya Diagnostic Centre Limited appears to be financially self-sufficient with no immediate plans for fundraising.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Vijaya Diagnostic Centre Ltd Q2 FY26 results?
Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this. - EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even. - CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion. - Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even. - Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate. - The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs.
What is Vijaya Diagnostic Centre Ltd share price analysis?
Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vijaya Diagnostic Centre Ltd planning capital expenditure?
FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.